AstraZeneca PLC (AZN) — closed signal from December 17, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 17, 2026.
Predicted vs. what happened
AZN price · publication thesis → realized outcomesplit-adjusted
$344.71 – $358.42Entry zone — fair-value band
$180.50Published — price the day we called it
$392.97Target — the price the thesis aimed for
$210.50Peak — highest point inside the window, not a realized return
$191.29Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 56 days.
Peak price
$210.50
peak on February 18, 2026 — not a realized returnPeak gain
+16.6%
peak, from the publication priceWindow close
$191.29
end-of-window price, context onlyDays to target
56
Window
December 17, 2025 – March 17, 2026
The thesis — published December 17, 2025
Predicted growth
+10%
over the measurement windowTarget price
$392.97
the price the thesis aimed forEntry zone
$344.71 – $358.42
the fair-value band we waited forPrice at publication
$180.50
published December 17, 2025Confidence
60%
how strongly the data lined upTimeframe
Short-term (0–3 months)
AstraZeneca may bounce because recent FDA approval for Enhertu with Perjeta can change short-term expectations and attract buyers. Market mood is still positive, but broader measures of trend are not yet supportive, so timing is important. Treat this as a short-term trade around the price floor rather than a long-term buy.
Primary drivers
- FDA approval can boost near-term cancer drug sales and story
- Recent price levels look oversold, raising chance of a short rally
- Defensive healthcare status can draw investors during uncertainty
- Weak internal fundamentals mean gains could reverse if news fades
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.